Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Angiotensin-converting–enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure. | Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease The PEACE Trial Investigators abstract The writing committee for the Prevention of Events with Angiotensin Converting Enzyme Inhibition PEACE Trial Eugene Braunwald M.D. Harvard Medical School and Brigham and Women s Hospital Boston Michael J. Domanski M.D. National Heart Lung and Blood Institute Bethesda Md. Sarah E. Fowler Ph.D. George Washington University Rockville Md. Nancy L. Geller Ph.D. National Heart Lung and Blood Institute Bernard J. Gersh M.D. Mayo Clinic Foundation Rochester Minn. Judith Hsia M.D. George Washington University Washington D.C. Marc A. Pfeffer M.D. Ph.D. Harvard Medical School and Brigham and Women s Hospital Madeline M. Rice Ph.D. George Washington University Rockville Md. Yves D. Rosenberg M.D. National Heart Lung and Blood Institute and Jean L. Rouleau M.D. University of Montreal Montreal takes responsibility for the content of this article. Address reprint requests to Dr. Braunwald at the TIMI Study Group Brigham and Women s Hospital 350 Longwood Ave. Boston MA 02115. The investigators and research coordinators who participated in the PEACE Trial are listed in the Appendix. N Engl J Med 2004 351 2058-68. Copyright 2004 Massachusetts Medical Society. background Angiotensin-converting-enzyme ACE inhibitors are effective in reducing the risk of heart failure myocardial infarction and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure. methods In the Prevention of Events with Angiotensin Converting Enzyme Inhibition PEACE Trial we tested the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of
